Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18098452 | 0.83 | MMP8 (0.37) | DGAT1MMP8ALDH1A1MEN1KMT2A | |
| SCHEMBL10838592 | 0.83 | MMP8 (0.37) | DGAT1MMP8ALDH1A1MEN1KMT2A | |
| SCHEMBL13788287 | 0.80 | MMP8 (0.44) | DGAT1MMP8KCNN4GAA | |
| SCHEMBL14341034 | 0.80 | MMP8 (0.35) | DGAT1MMP8 | |
| SCHEMBL10595182 | 0.80 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2DGAT1 | |
| SCHEMBL25131984 | 0.80 | SLC1A3 (0.38) | DGAT1MMP8 | |
| SCHEMBL15711664 | 0.80 | MMP8 (0.35) | GABRR1CYP1A2FOLH1NAALAD2DGAT1 | |
| SCHEMBL23772661 | 0.80 | MMP8 (0.46) | GABRR1CYP1A2MMP8ALDH1A1MEN1 | |
| SCHEMBL13039769 | 0.79 | DGAT1 (0.31) | DGAT1MMP8KMT2A | |
| SCHEMBL12598259 | 0.79 | MMP8 (0.45) | DGAT1MMP8ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458661-B1 | SEPARATION OF DIASTEREOISOMERS | BASELL POLIOLEFINE SRL (IT) | 2007-05-02 | — | — | EP | claimed |
| US-7067690-B2 | Separation of diastereoisomers | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2006-06-27 | — | — | US | claimed |
| US-20050171379-A1 | Separation of diastereoisomers | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2005-08-04 | — | — | US | claimed |
| CN-1608041-A | Separation of diastereomers | BASELL POLIOLEFINE SPA (IT) | 2005-04-20 | — | — | CN | claimed |
| EP-1458661-A1 | SEPARATION OF DIASTEREOISOMERS | Basell Poliolefine Italia S.p.A. (IT) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055831-A1 | SEPARATION OF DIASTEREOISOMERS | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2003-07-10 | — | — | WO | claimed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| EP-1458661-B1 | SEPARATION OF DIASTEREOISOMERS | BASELL POLIOLEFINE SRL (IT) | 2007-05-02 | — | — | EP | disclosed |
| US-7067690-B2 | Separation of diastereoisomers | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2006-06-27 | — | — | US | disclosed |
| US-20050171379-A1 | Separation of diastereoisomers | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2005-08-04 | — | — | US | disclosed |
| CN-1608041-A | Separation of diastereomers | BASELL POLIOLEFINE SPA (IT) | 2005-04-20 | — | — | CN | disclosed |
| EP-1458661-A1 | SEPARATION OF DIASTEREOISOMERS | Basell Poliolefine Italia S.p.A. (IT) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055831-A1 | SEPARATION OF DIASTEREOISOMERS | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | GABRR1 3239/4885CYP1A2 409/4885FOLH1 3266/4885 |
| US-20050171379-A1 | Separation of diastereoisomers | SSB, C9, CA1 | GABRR1 1896/4885CYP1A2 2438/4885FOLH1 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.